Uniqure NV (NASDAQ:QURE) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 25, 2016
Zacks Investment Research has upgraded Uniqure NV (NASDAQ:QURE) to Hold in a statement released on Wednesday September 21, 2016.
Boasting a price of $7.92, Uniqure NV (NASDAQ:QURE) traded 5.91% higher on the day. With the last stock price close down -21.70% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Uniqure NV has recorded a 50-day average of $8.21 and a two hundred day average of $10.29. Volume of trade was up over the average, with 270,294 shares of QURE changing hands over the typical 245,869
With a total market value of $0, Uniqure NV has with a one year low of $6.68 and a one year high of $24.50 .
Brief Synopsis About Uniqure NV (NASDAQ:QURE)
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson's Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington's disease, in which the Company has demonstrated preclinical proof of concept.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.